Pharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined the fray, testing its Ultomiris in a subset of severely ill patients. A biologic medicine, ...

- At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Atypical HUS affects both adults and children and many ...

Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an intravenous ...

Alexion Pharmaceuticals Inc. has demonstrated the commercial potential for rare disease drugs with its complement inhibitor Soliris (eculizumab) and long-lasting follow-up Ultomiris (ravulizumab) ...

Alexion and the UK’s National Institute for Health and Care Excellence (NICE) have agreed a confidence commercial discount for the paroxysmal nocturnal haemoglobinuria (PNH) treatment Ultomiris for ...

Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "ULTOMIRIS Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive ...

Ultomiris (ravulizumab-cwvz) is a prescription drug used to treat certain rare inflammatory conditions. Ultomiris can cause side effects that range from mild to serious. Examples include headache, ...

Bad news has struck first for AstraZeneca’s newly acquired Alexion rare disease franchise. AstraZeneca has decided to cap a phase 3 trial testing C5 inhibitor Ultomiris in the rare neurodegenerative ...

Ultomiris (ravulizumab-cwvz) is a brand-name drug prescribed for certain inflammatory diseases. Ultomiris comes as a solution for intravenous (IV) infusion. It’s given by a healthcare professional, ...

Ultomiris (ravulizumab-cwvz) is a brand-name injection that’s prescribed for certain rare diseases. As with other drugs, Ultomiris can cause side effects, such as upper respiratory tract infection and ...

According to the analysis conducted by Custom Market Insights (CMI), the Ultomiris drug market is projected to grow at a compound annual growth rate (CAGR) of 31.52% from 2025 to 2034. In 2025, the ...